1. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
2. J. Baril, R. B. Polland, R Raffi, M. Whelden, V. Rutkiewicz, and H. Brett-Smith (2002 ).Stavudine extended/prolonged release (XR/PRC) vs. stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.
3. Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
4. E. P. P. Bonnet, J. D. Yovanovitch, M. B. Mularczyk, R. Herve, E. Labau, and B. Perret . (2000 ).Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidemia in HIV-infected patients. Abstract 1538, retrieved September 28, 2000, from http://www.abstract-sonline.com/viewer/vi.ract.asp?controlNumber=25840sesslD=1285.
5. C. Bowonwatanuwong, P. Mootsikapun, K. Supparatpinyo, S. Tansuphaswadikul, R. Athisegran, and P. Pasook . (2001 ).A randomized, open label study to investigate abacavir (ABC) and lamivudine (3TC) as once daily (QD) components of a triple combination regimen (EPV40001). Abstract 4, retrieved February 22, 2002, from http://www.ias.se/ab stract/show.asp?abstract_id=4.